
Sensome develops innovative sensor technology that transforms invasive medical devices into connected healthcare devices. Their flagship product, the Clotild® connected guidewire, is designed for the treatment of ischemic stroke, utilizing impedance-based micro-sensors and machine learning algorithms to accurately identify biological tissues. This technology has potential applications in various medical fields, including oncology and peripheral artery disease. With a strong interdisciplinary team and support from experienced MedTech entrepreneurs, Sensome is positioned to make significant advancements in connected medical devices.

Sensome develops innovative sensor technology that transforms invasive medical devices into connected healthcare devices. Their flagship product, the Clotild® connected guidewire, is designed for the treatment of ischemic stroke, utilizing impedance-based micro-sensors and machine learning algorithms to accurately identify biological tissues. This technology has potential applications in various medical fields, including oncology and peripheral artery disease. With a strong interdisciplinary team and support from experienced MedTech entrepreneurs, Sensome is positioned to make significant advancements in connected medical devices.
Headquarters: Massy, France
Focus: Impedance-based tissue-sensing microchips for minimally invasive medical devices
Lead product: Clotild Smart Guidewire System (for acute ischemic stroke)
Employees (approx.): 41
Last known funding: Series B, Jan 2020; total reported ~$18.94M
Acute ischemic stroke treatment and intra-procedural tissue characterization in minimally invasive interventions.
2014
Medical devices / MedTech
Last reported round per company profiles
“Institutional investors including Idinvest Partners, Kurma Partners, Paris-Saclay Seed Fund, BNP Paribas Développement, and Asahi Intecc USA”